2cureX Investor Relations Material
Latest events
Investor Update
2cureX
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from 2cureX
Access all reports
2cureX AB is a medtech company focused on improving cancer treatment through functional drug sensitivity testing. Its flagship product, IndiTreat, is an in vitro diagnostic (IVD) test that helps predict a cancer patient’s response to different drugs, enabling personalized treatment plans. IndiTreat is designed to assist in treating colorectal, ovarian, and pancreatic cancers, among others. The company is headuqartered in Copenhagen, Denmark, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
2CUREX
Country
🇸🇪 Sweden